FleurirABX has an executive team with a wealth of experience:

Steven Volla, Chairman and Chief Executive Officer

Mr Volla has over 35 years leading both public & private healthcare companies including American Health Management, Universal Health Services, and as advisor and partner to American Securities Funds, and partner at MTS Health Partners. He was named Entrepreneur of the Year by Ernst & Young for turnaround of American Health Management. Mr. Volla served on boards of eight private and public companies controlled by private equity and fund managers in a broad array of health care, finance and retail entities. He holds an M.P.H. from University of California Los Angeles.

John L. Pace, Vice Chairman and Chief Scientific Officer

Dr. Pace is a distinguished senior scientist with 30 years of anti-infectives R&D experience. Dr. Pace is a named co-inventor on 20 U.S. patents including the MRSA antibacterial Vibativ (telavancin). He was the inventor of three vaccine clinical candidates and a technology. He contributed to advancement of 12 products into clinical evaluation including AvyCaz (ceftazidime/avibactam). Dr. Pace has held leadership positions with both leading pharmaceutical and successful start-up drug-development companies including Stiefel-GlaxoSmithKline, Novexel (acquired by AstraZeneca), Protez (acquired by Novartis), Theravance, Antex Biologics and Hoffmann-LaRoche (Roche Laboratories). Dr. Pace earned a Ph.D. in Food Science from the University of Maryland.

Dr. Susan Gardlik, Chief Operating Officer

Dr. Gardlik has 24 years pharmaceutical experience at GlaxoSmithKline, specializing in portfolio and project management. As VP of Drug Discovery Portfolio Management, she managed a global team providing strategic and operational portfolio management for 35+ units with a portfolio of nearly 300 projects. She earned a Ph.D. in Biochemistry from Duke University.

The executive team also has an established network of experts for consultation in: Regulatory, CMC, preclinical/clinical development, antibacterials, finance